Literature DB >> 27066792

Non-functioning pituitary adenomas: growth and aggressiveness.

Kristin Astrid Øystese1,2, Johan Arild Evang3,4, Jens Bollerslev3,4.   

Abstract

Pituitary adenomas (PAs) are common, comprising approximately one third of all intracranial tumors. Non-functioning pituitary adenomas (NFPAs) are the most common PAs. Although usually benign, the NFPAs represent therapeutic challenges because of their location close to the optic chiasm and nerves, and the proximity to the pituitary gland. The therapeutic alternatives are surgery and radiation. To date there is no effective medical treatment. NFPAs are classified according to different modalities, but there are no reliable marker of aggressiveness to guide the clinician in monitoring the patient. More information on growth patterns with constituent biological markers are needed to tailor the care of this patient group. Studies characterizing the membrane receptors of NFPAs have shown promising results, which may give rise to the development of medical treatment.

Entities:  

Keywords:  Aggressiveness; Growth kinetics; Non-functioning pituitary adenomas; Pituitary adenomas; Prognosis; Silent pituitary adenomas

Mesh:

Year:  2016        PMID: 27066792     DOI: 10.1007/s12020-016-0940-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  60 in total

1.  Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.

Authors:  Alessandra Fusco; Antonella Giampietro; Antonio Bianchi; Vincenzo Cimino; Francesca Lugli; Serena Piacentini; Margherita Lorusso; Anna Tofani; Germano Perotti; Libero Lauriola; Carmelo Anile; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 3.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

4.  SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.

Authors:  Misu Lee; Amelie Lupp; Nigel Mendoza; Niamh Martin; Rudi Beschorner; Jürgen Honegger; Jürgen Schlegel; Talia Shively; Elke Pulz; Stefan Schulz; Federico Roncaroli; Natalia S Pellegata
Journal:  Endocr Relat Cancer       Date:  2014-12-16       Impact factor: 5.678

5.  MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas.

Authors:  Gustavo Soto-Ares; Christine Cortet-Rudelli; Richard Assaker; Arnaud Boulinguez; C Dubest; Didier Dewailly; Jean Pierre Pruvo
Journal:  Eur J Endocrinol       Date:  2002-02       Impact factor: 6.664

6.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Authors:  Y Greenman; G Ouaknine; I Veshchev; I I Reider-Groswasser; Y Segev; N Stern
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

7.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

8.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

9.  Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures.

Authors:  Helene Halvorsen; Jon Ramm-Pettersen; Roger Josefsen; Pål Rønning; Sissel Reinlie; Torstein Meling; Jon Berg-Johnsen; Jens Bollerslev; Eirik Helseth
Journal:  Acta Neurochir (Wien)       Date:  2013-12-17       Impact factor: 2.216

10.  Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Authors:  Donato Iacovazzo; Eivind Carlsen; Francesca Lugli; Sabrina Chiloiro; Serena Piacentini; Antonio Bianchi; Antonella Giampietro; Marilda Mormando; Andrew J Clear; Francesco Doglietto; Carmelo Anile; Giulio Maira; Libero Lauriola; Guido Rindi; Federico Roncaroli; Alfredo Pontecorvi; Márta Korbonits; Laura De Marinis
Journal:  Eur J Endocrinol       Date:  2015-11-19       Impact factor: 6.664

View more
  9 in total

Review 1.  Prognostic factors of regrowth in nonfunctioning pituitary tumors.

Authors:  Gerald Raverot; Alexandre Vasiljevic; Emmanuel Jouanneau
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas.

Authors:  Dan Liu; Jiajia Li; Na Li; Miaolong Lu; Siqi Wen; Xianquan Zhan
Journal:  EPMA J       Date:  2020-08-13       Impact factor: 6.543

3.  Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.

Authors:  Marco Losa; Giorgio Spatola; Luigi Albano; Alessandra Gandolfi; Antonella Del Vecchio; Angelo Bolognesi; Pietro Mortini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

4.  Is pituitary MRI screening necessary in cluster headache?

Authors:  Lou Grangeon; Emer O'Connor; Daisuke Danno; Thanh Mai Pham Ngoc; Sanjay Cheema; Erling Tronvik; Indran Davagnanam; Manjit Matharu
Journal:  Cephalalgia       Date:  2021-01-06       Impact factor: 6.292

Review 5.  Histopathological classification of non-functioning pituitary neuroendocrine tumors.

Authors:  Emilija Manojlovic-Gacic; Britt Edén Engström; Olivera Casar-Borota
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  Clinical and Pathological Aspects of Silent Pituitary Adenomas.

Authors:  Juliana Drummond; Federico Roncaroli; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

7.  Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Authors:  Tomas Mickevicius; Alvita Vilkeviciute; Brigita Glebauskiene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 8.  Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.

Authors:  Sam Ng; Mahmoud Messerer; Julien Engelhardt; Michaël Bruneau; Jan Frederick Cornelius; Luigi Maria Cavallo; Giulia Cossu; Sebastien Froelich; Torstein R Meling; Dimitrios Paraskevopoulos; Henry W S Schroeder; Marcos Tatagiba; Idoya Zazpe; Moncef Berhouma; Roy T Daniel; Edward R Laws; Engelbert Knosp; Michael Buchfelder; Henri Dufour; Stéphane Gaillard; Timothée Jacquesson; Emmanuel Jouanneau
Journal:  Acta Neurochir (Wien)       Date:  2021-08-08       Impact factor: 2.816

9.  FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Authors:  Bin Zhu; Juan Wang; Lingling Qin; Lei Wang; Yanfei Zheng; Lei Zhang; Wei Wang
Journal:  Biosci Rep       Date:  2018-11-09       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.